{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:25:13Z","timestamp":1717028713542},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T00:00:00Z","timestamp":1715040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T00:00:00Z","timestamp":1715040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s00108-024-01717-z","type":"journal-article","created":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T18:01:54Z","timestamp":1715104914000},"page":"538-544","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mukoviszidose im Kindes- und im Erwachsenenalter","Cystic fibrosis in childhood and adulthood"],"prefix":"10.1007","volume":"65","author":[{"given":"Zulfiya","family":"Syunyaeva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus A.","family":"Mall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirjam","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,7]]},"reference":[{"key":"1717_CR1","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1001\/archpedi.1938.01980140114013","volume":"56","author":"DH Andersen","year":"1938","unstructured":"Andersen DH (1938) Cystic fibrosis of the pancreas and its relation to celiac disease: A clinical and pathologic study. American Journal of Diseases of Children 56:344\u2013399","journal-title":"American Journal of Diseases of Children"},{"key":"1717_CR2","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1164\/rccm.202011-4153OC","volume":"204","author":"PR Burgel","year":"2021","unstructured":"Burgel\u00a0PR, Durieu\u00a0I, Chiron\u00a0R et\u00a0al (2021) Rapid Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease. Am J Respir Crit Care Med 204:64\u201373","journal-title":"Am J Respir Crit Care Med"},{"key":"1717_CR3","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.jcf.2022.09.011","volume":"21","author":"C Castellani","year":"2022","unstructured":"Castellani\u00a0C, De Boeck\u00a0K, De Wachter\u00a0E et\u00a0al (2022) ECFS standards of care on CFTR-related disorders: Updated diagnostic criteria. J\u00a0Cyst Fibros 21:908\u2013921","journal-title":"J Cyst Fibros"},{"key":"1717_CR4","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","volume":"17","author":"C Castellani","year":"2018","unstructured":"Castellani\u00a0C, Duff\u00a0AJA, Bell\u00a0SC et\u00a0al (2018) ECFS best practice guidelines: the 2018 revision. J\u00a0Cyst Fibros 17:153\u2013178","journal-title":"J Cyst Fibros"},{"key":"1717_CR5","doi-asserted-by":"crossref","unstructured":"Daines CL, Tullis E, Costa S et\u00a0al (2023) Long-term safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a\u00a0192-week open-label extension study. Eur Respir\u00a0J 62:","DOI":"10.1183\/13993003.02029-2022"},{"key":"1717_CR6","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/j.jpeds.2005.08.009","volume":"147","author":"JE Dankert-Roelse","year":"2005","unstructured":"Dankert-Roelse\u00a0JE, Merelle\u00a0ME (2005) Review of outcomes of neonatal screening for cystic fibrosis versus non-screening in Europe. J\u00a0Pediatr 147:S15\u201320","journal-title":"J Pediatr"},{"key":"1717_CR7","first-page":"753","volume":"86","author":"G Fanconi","year":"1936","unstructured":"Fanconi G, Uehlinger E, Knauer C (1936) Das Coeliakiesyndrom bei angeborener zystischer Pankreasfibromatose und Bronchiektasien. Wien Med Wochenschr 86:753\u2013756","journal-title":"Wien Med Wochenschr"},{"key":"1717_CR8","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.jpeds.2016.09.064","volume":"181S","author":"PM Farrell","year":"2017","unstructured":"Farrell\u00a0PM, White\u00a0TB, Ren\u00a0CL et\u00a0al (2017) Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation. J\u00a0Pediatr 181S:S4\u2013S15","journal-title":"J Pediatr"},{"key":"1717_CR9","volume-title":"2022","author":"CF Foundation","year":"2021","unstructured":"Foundation\u00a0CF (2021) 2022. Cystic Fibrosis Foundation\u00a0Patient Registry Highlights, Bethesda, Maryland"},{"key":"1717_CR10","unstructured":"Gmbh VPG Kaftrio 37,5\u202fmg\/25\u202fmg\/50\u202fmg\/-75\u202fmg\/50\u202fmg\/100\u202fmg Filmtabletten."},{"key":"1717_CR11","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1159\/000530261","volume":"50","author":"E Gomez-Montes","year":"2023","unstructured":"Gomez-Montes\u00a0E, Salcedo Lobato\u00a0E, Galindo Izquierdo\u00a0A et\u00a0al (2023) Prenatal Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A\u00a0Promising Way to Change the Impact of Cystic Fibrosis. Fetal Diagn Ther 50:136\u2013142","journal-title":"Fetal Diagn Ther"},{"key":"1717_CR12","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/S0140-6736(23)01608-2","volume":"402","author":"SY Graeber","year":"2023","unstructured":"Graeber\u00a0SY, Mall\u00a0MA (2023) The future of cystic fibrosis treatment: from disease mechanisms to novel therapeutic approaches. Lancet 402:1185\u20131198","journal-title":"Lancet"},{"key":"1717_CR13","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1164\/rccm.202201-0219OC","volume":"206","author":"SY Graeber","year":"2022","unstructured":"Graeber\u00a0SY, Renz\u00a0DM, Stahl\u00a0M et\u00a0al (2022) Effects of Elexacaftor\/Tezacaftor\/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Patients with Cystic Fibrosis and One or Two F508del Alleles. Am J Respir Crit Care Med 206:311\u2013320","journal-title":"Am J Respir Crit Care Med"},{"key":"1717_CR14","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1164\/rccm.202110-2249OC","volume":"205","author":"SY Graeber","year":"2022","unstructured":"Graeber\u00a0SY, Vitzthum\u00a0C, Pallenberg\u00a0ST et\u00a0al (2022) Effects of Elexacaftor\/Tezacaftor\/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two F508del Alleles. Am J Respir Crit Care Med 205:540\u2013549","journal-title":"Am J Respir Crit Care Med"},{"key":"1717_CR15","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1056\/NEJMra2216474","volume":"389","author":"H Grasemann","year":"2023","unstructured":"Grasemann\u00a0H, Ratjen\u00a0F (2023) Cystic fibrosis. N\u00a0Engl J Med 389:1693\u20131707","journal-title":"N Engl J Med"},{"key":"1717_CR16","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/S2213-2600(13)70026-2","volume":"1","author":"H Grasemann","year":"2013","unstructured":"Grasemann\u00a0H, Ratjen\u00a0F (2013) Early lung disease in cystic fibrosis. Lancet Respir Med 1:148\u2013157","journal-title":"Lancet Respir Med"},{"key":"1717_CR17","first-page":"212","volume-title":"Cystische Fibrose","author":"M Griese","year":"2013","unstructured":"Griese M, Reinhardt D (2013) Differentialdiagnose pathologischer Schwei\u00dftestresultate. In: Reinhardt DGM, Kraemer R, Sch\u00f6ni MH (Hrsg) Cystische Fibrose. Springer-Verlag, S 212"},{"key":"1717_CR18","doi-asserted-by":"crossref","unstructured":"Jain R, Magaret A, Vu PT et\u00a0al (2022) Prospectively evaluating maternal and fetal outcomes in the era of CFTR modulators: the MAYFLOWERS observational clinical trial study design. BMJ Open Respir Res 9:","DOI":"10.1136\/bmjresp-2022-001289"},{"key":"1717_CR19","doi-asserted-by":"publisher","first-page":"e01015","DOI":"10.1002\/prp2.1015","volume":"10","author":"R Kos","year":"2022","unstructured":"Kos\u00a0R, Neerincx\u00a0AH, Fenn\u00a0DW et\u00a0al (2022) Real-life efficacy and safety of elexacaftor\/tezacaftor\/ivacaftor on severe cystic fibrosis lung disease patients. Pharmacol Res Perspect 10:e1015","journal-title":"Pharmacol Res Perspect"},{"key":"1717_CR20","volume-title":"Wosniok","author":"LMBJ N\u00e4hrlich","year":"2023","unstructured":"N\u00e4hrlich\u00a0LMBJ (2023) Wosniok. Berichtsband, Bd. 2022. Deutsches Mukoviszidose-Register"},{"key":"1717_CR21","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jcf.2023.02.004","volume":"22","author":"A Lopez","year":"2023","unstructured":"Lopez\u00a0A, Daly\u00a0C, Vega-Hernandez\u00a0G et\u00a0al (2023) Elexacaftor\/tezacaftor\/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del. J\u00a0Cyst Fibros 22:607\u2013614","journal-title":"J Cyst Fibros"},{"key":"1717_CR22","doi-asserted-by":"crossref","unstructured":"Loske J, Voller M, Lukassen S et\u00a0al (2024) Pharmacological Improvement of CFTR Function Rescues Airway Epithelial Homeostasis and Host Defense in Children with Cystic Fibrosis. Am J Respir Crit Care Med","DOI":"10.1164\/rccm.202310-1836OC"},{"key":"1717_CR23","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1164\/rccm.201910-1943SO","volume":"201","author":"MA Mall","year":"2020","unstructured":"Mall\u00a0MA, Mayer-Hamblett\u00a0N, Rowe\u00a0SM (2020) Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications. Am J Respir Crit Care Med 201:1193\u20131208","journal-title":"Am J Respir Crit Care Med"},{"key":"1717_CR24","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.jcf.2021.07.017","volume":"21","author":"CJ Mckinzie","year":"2022","unstructured":"Mckinzie\u00a0CJ, Doligalski\u00a0CT, Lobritto\u00a0SJ et\u00a0al (2022) Use of elexacaftor\/tezacaftor\/ivacaftor in liver transplant patients with cystic fibrosis. J\u00a0Cyst Fibros 21:227\u2013229","journal-title":"J Cyst Fibros"},{"key":"1717_CR25","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","volume":"381","author":"PG Middleton","year":"2019","unstructured":"Middleton\u00a0PG, Mall\u00a0MA, Drevinek\u00a0P et\u00a0al (2019) Elexacaftor-tezacaftor-Ivacaftor for cystic fibrosis with a\u00a0single Phe508del allele. N\u00a0Engl J Med 381:1809\u20131819","journal-title":"N Engl J Med"},{"key":"1717_CR26","doi-asserted-by":"publisher","first-page":"220005","DOI":"10.1183\/20734735.0005-2022","volume":"18","author":"K Montemayor","year":"2022","unstructured":"Montemayor\u00a0K, Tullis\u00a0E, Jain\u00a0R et\u00a0al (2022) Management of pregnancy in cystic fibrosis. Breathe (sheff) 18:220005","journal-title":"Breathe (sheff)"},{"issue":"10","key":"1717_CR27","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/ng.2745","volume":"45","author":"R Patrick","year":"2013","unstructured":"Patrick R, Sosnay KR, Siklosi F, Van Goor K (2013) Nature Genetics 45(10):1160\u20131167. https:\/\/doi.org\/10.1038\/ng.2745","journal-title":"Nature Genetics"},{"key":"1717_CR28","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/ppul.25779","volume":"57","author":"H Ragan","year":"2022","unstructured":"Ragan\u00a0H, Autry\u00a0E, Bomersback\u00a0T et\u00a0al (2022) The use of elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis postliver transplant: A\u00a0case series. Pediatr Pulmonol 57:411\u2013417","journal-title":"Pediatr Pulmonol"},{"key":"1717_CR29","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","volume":"365","author":"BW Ramsey","year":"2011","unstructured":"Ramsey\u00a0BW, Davies\u00a0J, Mcelvaney\u00a0NG et\u00a0al (2011) A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N\u00a0Engl J Med 365:1663\u20131672","journal-title":"N Engl J Med"},{"key":"1717_CR30","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1126\/science.2475911","volume":"245","author":"JR Riordan","year":"1989","unstructured":"Riordan\u00a0JR, Rommens\u00a0JM, Kerem\u00a0B et\u00a0al (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245:1066\u20131073","journal-title":"Science"},{"key":"1717_CR31","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1001\/jamapediatrics.2022.2674","volume":"176","author":"M Rosenfeld","year":"2022","unstructured":"Rosenfeld\u00a0M, Ostrenga\u00a0J, Cromwell\u00a0EA et\u00a0al (2022) Real-world Associations of US Cystic Fibrosis Newborn Screening Programs With Nutritional and Pulmonary Outcomes. JAMA Pediatr 176:990\u2013999","journal-title":"JAMA Pediatr"},{"key":"1717_CR32","doi-asserted-by":"crossref","unstructured":"Schaupp L, Addante A, Voller M et\u00a0al (2023) Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis. Eur Respir\u00a0J 62:","DOI":"10.1183\/13993003.02153-2022"},{"key":"1717_CR33","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.jcf.2022.09.005","volume":"21","author":"I Sermet-Gaudelus","year":"2022","unstructured":"Sermet-Gaudelus\u00a0I, Girodon\u00a0E, Vermeulen\u00a0F et\u00a0al (2022) ECFS standards of care on CFTR-related disorders: Diagnostic criteria of CFTR dysfunction. J\u00a0Cyst Fibros 21:922\u2013936","journal-title":"J Cyst Fibros"},{"key":"1717_CR34","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/j.chest.2021.07.024","volume":"160","author":"M Shteinberg","year":"2021","unstructured":"Shteinberg\u00a0M, Taylor-Cousar\u00a0JL, Durieu\u00a0I et\u00a0al (2021) Fertility and Pregnancy in Cystic Fibrosis. Chest 160:2051\u20132060","journal-title":"Chest"},{"key":"1717_CR35","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jcf.2021.10.007","volume":"21","author":"O Sommerburg","year":"2022","unstructured":"Sommerburg\u00a0O, Stahl\u00a0M, Hammerling\u00a0S et\u00a0al (2022) Final results of the southwest German pilot study on cystic fibrosis newborn screening\u2014Evaluation of an IRT\/PAP protocol with IRT-dependent safety net. J\u00a0Cyst Fibros 21:422\u2013433","journal-title":"J Cyst Fibros"},{"key":"1717_CR36","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1164\/rccm.202102-0278OC","volume":"204","author":"M Stahl","year":"2021","unstructured":"Stahl\u00a0M, Steinke\u00a0E, Graeber\u00a0SY et\u00a0al (2021) Magnetic Resonance Imaging Detects Progression of Lung Disease and Impact of Newborn Screening in Preschool Children with Cystic Fibrosis. Am J Respir Crit Care Med 204:943\u2013953","journal-title":"Am J Respir Crit Care Med"},{"key":"1717_CR37","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1164\/rccm.201604-0893OC","volume":"195","author":"M Stahl","year":"2017","unstructured":"Stahl\u00a0M, Wielputz\u00a0MO, Graeber\u00a0SY et\u00a0al (2017) Comparison of Lung Clearance Index and Magnetic Resonance Imaging for Assessment of Lung Disease in Children with Cystic Fibrosis. Am J Respir Crit Care Med 195:349\u2013359","journal-title":"Am J Respir Crit Care Med"},{"key":"1717_CR38","first-page":"100690","volume":"32","author":"S Sutharsan","year":"2023","unstructured":"Sutharsan\u00a0S, Dillenhoefer\u00a0S, Welsner\u00a0M et\u00a0al (2023) Impact of elexacaftor\/tezacaftor\/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry. Lancet Reg Health. Eur 32:100690","journal-title":"Eur"},{"key":"1717_CR39","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.jcf.2022.04.005","volume":"21","author":"S Szentpetery","year":"2022","unstructured":"Szentpetery\u00a0S, Foil\u00a0K, Hendrix\u00a0S et\u00a0al (2022) A case report of CFTR modulator administration via carrier mother to treat meconium ileus in a\u00a0F508del homozygous fetus. J\u00a0Cyst Fibros 21:721\u2013724","journal-title":"J Cyst Fibros"},{"key":"1717_CR40","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.jcf.2021.03.006","volume":"20","author":"JL Taylor-Cousar","year":"2021","unstructured":"Taylor-Cousar\u00a0JL, Jain\u00a0R (2021) Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation. J\u00a0Cyst Fibros 20:402\u2013406","journal-title":"J Cyst Fibros"},{"key":"1717_CR41","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1164\/rccm.201309-1659OC","volume":"189","author":"MO Wielputz","year":"2014","unstructured":"Wielputz\u00a0MO, Puderbach\u00a0M, Kopp-Schneider\u00a0A et\u00a0al (2014) Magnetic resonance imaging detects changes in structure and perfusion, and response to therapy in early cystic fibrosis lung disease. Am J Respir Crit Care Med 189:956\u2013965","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-024-01717-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-024-01717-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-024-01717-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T16:03:44Z","timestamp":1716998624000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-024-01717-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,7]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["1717"],"URL":"https:\/\/doi.org\/10.1007\/s00108-024-01717-z","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,7]]},"assertion":[{"value":"24 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Z.\u00a0Syunyaeva erhielt Honorare f\u00fcr Vortr\u00e4ge und Reiseunterst\u00fctzung von der Fa. Vertex Pharmaceuticals in den letzten 36\u00a0Monaten. M.A.\u00a0Mall erhielt F\u00f6rdermittel von der Deutschen Forschungsgemeinschaft (DFG), dem Bundesministerium f\u00fcr Bildung und Forschung (BMBF), dem Innovationsfonds des Gemeinsamen Bundesausschuss (GB-A) und Vertex Pharmaceuticals in den letzten 36\u00a0Monaten. Dar\u00fcber hinaus erhielt M.\u00a0Mall Beratungshonorare von AbbVie, Antabio, Arrowhead Pharmaceuticals, Boehringer Ingelheim, Enterprise Therapeutics, Kither Biotech, Prieris, Recode, Santhera, SpliSense und Vertex Pharmaceuticals in den letzten 36\u00a0Monaten. M.\u00a0Mall erhielt zudem Reiseunterst\u00fctzung von Boehringer Ingelheim und Vertex Pharmaceuticals in den letzten 36\u00a0Monaten. M.\u00a0Mall nahm an Advisory boards von AbbVie, Antabio, Arrowhead Pharmaceuticals, Boehringer Ingelheim, Enterprise Therapeutics, Kither Biotech, Pari und Vertex Pharmaceuticals teil. M.\u00a0Mall ist \u201eFellow der European Respiratory Society\u201c (FERS). M.\u00a0Stahl nimmt am Berlin Institute of Health (BIH) Charit\u00e9 Clinician Scientist Program teil, das von der Charit\u00e9\u00a0\u2013 Universit\u00e4tsmedizin Berlin und dem BIH finanziert wird. M.\u00a0Stahl berichtet \u00fcber einen Independent Research Innovation Award, Honorare f\u00fcr Vortr\u00e4ge und die Teilnahme an Beratungsgremien, alle von Vertex Pharmaceuticals Incorporated, au\u00dferhalb der eingereichten Arbeit. Sie ist Vorsitzende der Deutschen Forschungsgemeinschaft Mukoviszidose (FGM), Schatzmeisterin der Gesellschaft f\u00fcr P\u00e4diatrische Pulmologie (GPP) und war Sekret\u00e4rin der Gruppe Mukoviszidose der Pediatric Assembly der European Respiratory Society (ERS).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}